Search research articles
Contact Us
Filters
Showing results (51-60 of 193) with videos related to
Page
of 20
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 7, 2002
The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4
Maha Katabi, Shala Yuan, Helen Chan, et al.
Oncotarget
|
December 2, 2017
The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells
Holly C Lewis, Raghavan Chinnadurai, Steven E Bosinger, et al.
The Annals of Thoracic Surgery
|
January 23, 2003
Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model
Abdulaziz Al-Khaldi, Hilal Al-Sabti, Jacques Galipeau, et al.
Journal of Multiple Sclerosis
|
July 3, 2015
Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients
Jakob Habib, Jiusheng Deng, Neil Lava, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 21, 2020
Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination
Andrea Pennati, Emily A Nylen, Ian D Duncan, et al.
Cell Reports
|
February 13, 2020
CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury
Jayeeta Giri, Rahul Das, Emily Nylen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 10, 2014
IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells
Raghavan Chinnadurai, Ian B Copland, Seema R Patel, et al.
Blood
|
August 25, 2005
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
Nicoletta Eliopoulos, John Stagg, Laurence Lejeune, et al.
Experimental Hematology
|
January 13, 2009
Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation
François Mercier, Yury Monczak, Moïra François, et al.
Biomed Research International
|
December 19, 2013
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases
Raghavan Chinnadurai, Edmund K Waller, Jacques Galipeau, et al.
Page
of 20
Search research articles
Search
Showing results (51-60 of 193) with videos related to
Sort By:
Page
of 20
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 7, 2002
The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4
Maha Katabi, Shala Yuan, Helen Chan, et al.
Oncotarget
|
December 2, 2017
The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells
Holly C Lewis, Raghavan Chinnadurai, Steven E Bosinger, et al.
The Annals of Thoracic Surgery
|
January 23, 2003
Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model
Abdulaziz Al-Khaldi, Hilal Al-Sabti, Jacques Galipeau, et al.
Journal of Multiple Sclerosis
|
July 3, 2015
Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients
Jakob Habib, Jiusheng Deng, Neil Lava, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
May 21, 2020
Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination
Andrea Pennati, Emily A Nylen, Ian D Duncan, et al.
Cell Reports
|
February 13, 2020
CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury
Jayeeta Giri, Rahul Das, Emily Nylen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 10, 2014
IDO-independent suppression of T cell effector function by IFN-γ-licensed human mesenchymal stromal cells
Raghavan Chinnadurai, Ian B Copland, Seema R Patel, et al.
Blood
|
August 25, 2005
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
Nicoletta Eliopoulos, John Stagg, Laurence Lejeune, et al.
Experimental Hematology
|
January 13, 2009
Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation
François Mercier, Yury Monczak, Moïra François, et al.
Biomed Research International
|
December 19, 2013
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases
Raghavan Chinnadurai, Edmund K Waller, Jacques Galipeau, et al.
Page
of 20